Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.

Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T. · 2020

Read Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. by Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7163451.txt.

Introduction

Chen and co-authors test a two-drug combination against hard-to-treat KRAS mutant colorectal cancer cells, in Theranostics. Mutations in KRAS blunt the antibody drug cetuximab, a mainstay for metastatic colorectal cancer. The team paired cetuximab with beta-elemene, a compound from the Chinese herb Curcumae Rhizoma, hunting for a different killing route.

The pair worked in synergy, with the best effect at 125 micrograms per millilitre of beta-elemene plus 25 of cetuximab. Death was not the usual apoptosis: the cells accumulated iron-driven reactive oxygen, lost their glutathione shield, and showed the protein pattern of ferroptosis, an iron-based death program. The combination also blocked the shape-shifting linked to spread, and slowed tumors in an animal model.

Catalog record

CREATORChen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7163451

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation By Peng Chen, Xuejie Li, Ruonan Zhang, Shuiping Liu, Yu Xiang, Mingming Zhang, Xiaying Chen, Ting Pan, Lili Yan, Jiao Feng, Ting Duan, Da Wang Published in: Theranostics DOI: 10.7150/thno.44705 ABSTRACT Background and Purpose: RAS mutations limit the effectiveness of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in combination with chemotherapy for metastatic colorectal cancer (mCRC) patients. Therefore, new cell death forms have focused on identifying indirect targets to inhibit Ras-induced oncogenesis. Recently, emerging evidence has shown the potential of triggering ferroptosis for cancer therapy, particularly for eradicating aggressive malignancies that are resistant to traditional therapies. Methods: KRAS mutant CRC cell HCT116 and Lovo were treated with cetuximab and β-elemene, a bioactive compound isolated from Chinese herb Curcumae Rhizoma. Ferroptosis and epithelial-mesenchymal transformation (EMT) were detected in vitro and in vivo. Orthotopic CRC animal model were established and the tumor growth was monitored by IVIS bioluminescence imaging. Tumor tissues were collected to determine ferroptosis effect and the expression of EMT markers after the treatment. Results: CCK-8 assay showed that synergetic effect was obtained when 125 µg/ml β-elemene was combined with 25 µg/ml cetuximab in KRAS mutant CRC cells. AV/PI staining suggested a non-apoptotic mode of cell death after the treatment with β-elemene and cetuximab. In vitro, β-elemene in combination with cetuximab was shown to induce iron-dependent reactive oxygen species (ROS) accumulation, glutathione (GSH) depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) in KRAS mutant CRC cells. Meanwhile, combinative treatment of β-elemene and cetuximab inhibited cell migration and decreased the expression of mesenchymal markers (Vimentin, N-cadherin, Slug, Snail and MMP-9), but promoted the expression of epithelial marker E-cadherin. Moreover, ferroptosis inhibitors but not other cell death suppressors abrogated the effect of β-elemene in combination with cetuximab on KRAS mutant CRC cells. In vivo, co-treatment with β-elemene and cetuximab inhibited KRAS mutant tumor growth and lymph nodes metastases. Conclusions: Our data for the first time suggest that the natural product β-elemene is a new ferroptosis inducer and combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant CRC cells by inducing ferroptosis and inhibiting EMT, which will hopefully provide a prospective strategy for CRC patients with RAS mutations. INTRODUCTION Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second most common cause of cancer-related mortality around the world 1. Although the recent progress of diagnosis and therapeutic strategies has been developed, CRC remains one of the most deadly human cancers due to the resistance to anticancer treatment and disease progression. Advances in the treatment of metastatic colorectal cancer (mCRC) have been made in recent years and mainly consist of the monoclonal antibodies against epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) with the combination of chemotherapy. It has been recommended that anti-EGFR antibodies, such as cetuximab or panitumumab, in combination with chemotherapy are effective therapeutic approaches only for mCRC patients with RAS wild-type 2. Whereas, their effectiveness is often limited by intrinsic drug resistance, due to downstream KRAS mutations. RAS mutations are present in about 50% of CRC and they greatly hinder the therapeutic efficacy of EGFR inhibitors 3. Therefore, developing new cell death forms based on indirect targets to RAS mutations are urgently needed. Ferroptosis is a newly discovered cell death form, which is characterized by iron-dependent accumulation of lethal lipid peroxidation 4, 5. It is known that ferroptosis is distinct from apoptosis, necrosis, and autophagy at genetical, biochemical, and morphological level 6. To date, emerging evidence has shown the potential of triggering ferroptosis for cancer therapy, particularly for eradicating aggressive malignancies that are resistant to traditional therapies 7. Recently, it was interestingly found that those therapy-resistant cancer cells, which commonly undergo epithelial-mesenchymal transformation (EMT), were more likely to be killed by ferroptosis inducers, when compared with nonresistant cancer cells 8-10. So, induction of ferroptosis has emerged as a therapeutic strategy to trigger cancer cell death for therapy-resistant cancer cells. β-elemene, a bioactive compound isolated from Chinese herb Curcumae Rhizoma, exhibits a spectral anticancer effect and is used in various cancer types, including CRC 11, 12. However, its role in ferroptosis and the sensitivity of KRAS mutant CRC cells to cetuximab treatment has not yet been reported. Here, we for the first time demonstrated combinative treatment of β-elemene and cetuximab induced ferroptotic cell death in KRAS mutant CRC cell HCT116, accompanied with decreased cell viability and increased iron-dependent accumulation of lipid peroxidation in these cancer cells. The ferroptosis rescue agents but not pan-caspase inhibitor, autophagy inhibitor, or necroptosis inhibitor abrogated the cell death induced by the treatment with β-elemene and cetuximab, suggesting ferroptosis contributed to cell death from β-elemene treatment in combination with cetuximab. Meanwhile, we showed that combinative treatment of β-elemene and cetuximab could inhibit the migration of KRAS mutant CRC cells by suppressing EMT. Taken together, our data suggest that the natural product β-elemene is a new ferroptosis inducer and combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant CRC cells by inducing ferroptosis and inhibiting EMT, which will hopefully provide a prospective strategy for CRC patients with RAS mutations. MATERIALS AND METHODS Cell lines The human colon cancer cell lines HCT116, Lovo and CaCO2 were purchased from ATCC (LGC Standards SLU, Barcelona, Spain). The cell lines were maintained in Mccoy's 5A Medium (#GR16600-S) and DMEM/F12 (#GR12400-S) with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 µg/ml streptomycin (Invitrogen), and 2 mM L-glutamine at 37 ℃ in a humidified atmosphere of 95% air and 5% CO2. The fetal bovine serum was purchased from Corille (184590, Australia). Reagents and Antibodies β-elemene (>98%) (#E4418) was purchased from LKT. Stock solution at 100 mg/ml was made in ethanol and stored at -4°C. Cetuximab (#33657) was purchased from MCE. Antibodies against GPX4 (#GR251529-34), HO-1 (#GR3187585-3), Glutaminase (#GR3299063-1), SLC40A1 (#GR215168-39), Transferrin (#GR3207592-9), SLC7A11 (#GR3235736-6) were purchased from Abcam. N-Cadherin (#13116S), E-Cadherin (#14472S), MMP9 (#13667S), snail (#3879T), slug (#9585T), and GAPDH (#2118S) antibodies were obtained from Cell Signaling Technology. Vimentin (#SA10106DB) was purchased from ABGENT. Ki67 (#66434-1-Ig) was purchased from Proteintech. Deferoxamine (#CS-4479), Ferrostain-1 (#HY-100579), Necrostain-1 (#HY-15760) were purchased from MCE. Z-VAD-FMK (#V116) was obtained from Sigma Aldrich. Liproxstatin-1 (#S7699) and RSL3 (#S8155) were purchased from Selleck Chemical. Measurement of Cell Viability and Percentage of cell death Cell viability was evaluated using the Cell Counting Kit-8 (CCK-8) (LJ621, DOJINDO, JAPAN) according to the manufacturer's instructions. Cells were seeded in 96-well flat bottom microtiter plates at a density of 5000 cells per well. The absorbance was measured on a microplate reader (Synergy HT, Bio-Tek, USA) at 450 nm. Phartmingen annexin V-FITC Apoptosis Ddtection Kit I (BD, USA) was used to detect percentage of cell death and the estimation procedure was performed according to the manufacturer's instructions. 2×106 cells were seeded into a 6 cm dish. After attachment overnight, cells were washed twice with PBS and the medium was replaced medium with different drugs for 24 h. All cells including the floating cells in the culture medium were harvested. The cells were resuspended in ice-cold 1×binding buffer at a concentration of 1×106

Read the complete text